Govt, pharma industry lean on trade talks to soften Trump’s drug tariff plan
The Indian government and pharmaceutical industry are leveraging ongoing trade negotiations with the US to seek relief from President Donald Trump's proposed tariffs on imported generic medicines. The US accounts for $9.47 billion, or 30.4%, of India's total pharmaceutical exports, making the tariffs a significant risk for the sector. Officials believe the tariff announcement is a negotiating tactic rather than a final policy, aimed at pressuring India for concessions in broader trade discussions.